Malignant Melanoma – Landscape & Forecast – Disease Landscape & Forecast

The introduction of immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy (Bristol Myers Squibb), and Tecentriq (Roche / Genentech; United States only), as well as BRAF/MEK inhibitor combinations, such as Roche / Genentech’s Zelboraf + Cotellic, Novartis’s Tafinlar + Mekinist, and Pfizer / Array BioPharma’s Braftovi + Mektovi, has significantly changed the treatment landscape for malignant melanoma in both the resectable and metastatic settings. Nonetheless, opportunities remain for novel agents specifically targeting the underrepresented BRAF wild-type unresectable or metastatic population. With the expected introduction of novel agents and combination regimens, the malignant melanoma treatment paradigm will continue to evolve. In such a dynamic indication, marketed drugs need to be carefully positioned to achieve optimal uptake.

Questions Answered:

  • How large are the clinically and commercially relevant malignant melanoma drug-treatable populations? Will drug-treatment rates increase over the forecast period?
  • What is the current treatment landscape in malignant melanoma? Which currently approved drugs are the most important and why?
  • Which drugs in late-phase development are poised to change the treatment landscape for malignant melanoma and how? What sales / uptake could these drugs secure in the malignant melanoma market?
  • What are the key drivers and constraints in the malignant melanoma market, and how will the market evolve over the forecast period?

Content Highlights

Geographies: United States, EU5, Japan.

Primary research: 19 country-specific interviews with thought-leading medical oncologists, supported by survey data collected for this and other Clarivate research.

Epidemiology: Diagnosed incidence of malignant melanoma by country, segmented by disease stage and BRAF mutation status.

Forecast: 10-year, annualized, drug-level sales and patient share of key malignant melanoma therapies through 2029, segmented by brands / generics and epidemiological subpopulations.

Emerging therapies: Phase III: 10 drugs; Phase II: 7 drugs.

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution Enhancement

Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Table of contents

  • Malignant Melanoma - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q4 2021
        • October 2021
      • Q3 2021
        • September 2021
      • Q2 2021
        • June 2021
        • May 2021
        • April 2021
      • Q1 2021
        • March 2021
        • February 2021
        • January 2021
      • Q4 2020
        • November 2020
      • Q3 2020
        • August 2020
    • Key Findings
      • Market Outlook
        • Key Findings
          • Major-Market Share of Malignant Melanoma Drug Classes: 2020
          • Major-Market Share of Malignant Melanoma Drug Classes: 2030
          • Drug-Treatable Population Share and Major-Market Sales Share in Malignant Melanoma: 2020
          • Drug-Treatable Population Share and Major-Market Sales Share in Malignant Melanoma: 2030
          • Population Positioning of Therapies in Malignant Melanoma
          • Malignant Melanoma SWOT Analysis
        • COVID-19: Market Forecast Impact
          • Expert Insights on Areas Market Forecast Impact From COVID-19
        • Market Drivers and Constraints
          • What Factors Are Driving the Market for Malignant Melanoma?
          • What Factors Are Constraining the Market for Malignant Melanoma?
          • Major-Market Sales of Key Agents Excluding Immune Checkpoint Inhibitors in Malignant Melanoma: 2020-2030
          • Major-Market Sales of Immune Checkpoint Inhibitors in Malignant Melanoma: 2020-2030
          • Major-Market Share of Malignant Melanoma Sales by Patient Population: 2020-2030
          • Major-Market Share of Immune Checkpoint Inhibitors in Malignant Melanoma by Patient Population: 2030
          • Share of Major-Market Sales of Nivolumab and Pembrolizumab in Malignant Melanoma by Therapeutic Use: 2030
        • Segment-Specific Trends
          • Patient-Share Dynamics of Agents in Resectable BRAF Mutation-Positive Stage IIB-III Malignant Melanoma in the United States: 2020-2030
          • Patient-Share Dynamics of Agents in Resectable BRAF Mutation-Positive Stage IIB-III Malignant Melanoma in Europe: 2020-2030
          • Patient-Share Dynamics of Agents in Resectable BRAF Mutation-Positive Stage IIB-III Malignant Melanoma in Japan: 2020-2030
          • Patient-Share Dynamics of Agents in Resectable BRAF Wild-Type Stage IIB-III Malignant Melanoma in the United States: 2020-2030
          • Patient Share Dynamics of Agents in Resectable BRAF Wild-Type Stage IIB-III Malignant Melanoma in Europe: 2020-2030
          • Patient Share Dynamics of Agents in Resectable BRAF Wild-Type Stage IIB-III Malignant Melanoma in Japan: 2020-2030
          • Patient-Share Dynamics of Key Therapies in First-Line BRAF Mutation-Positive Unresectable or Metastatic Malignant Melanoma in the United States: 2020-2030
          • Patient-Share Dynamics of Key Therapies in First-Line BRAF Mutation-Positive Unresectable or Metastatic Malignant Melanoma in Europe: 2020-2030
          • Patient-Share Dynamics of Key Therapies in First-Line BRAF Wild-Type Unresectable or Metastatic Malignant Melanoma in the United States: 2020-2030
          • Patient-Share Dynamics of Key Therapies in First-Line BRAF Wild-Type Unresectable or Metastatic Malignant Melanoma in Europe: 2020-2030
          • Patient-Share Dynamics of Key Therapies in Second-Line BRAF-Mutation-Positive Unresectable or Metastatic Malignant Melanoma in the United States: 2020-2030
          • Patient Share Dynamics of Key Therapies in Second-Line BRAF-Mutation-Positive Unresectable or Metastatic Malignant Melanoma in Europe: 2020-2030
          • Patient-Share Dynamics of Key Therapies in Third- and Fourth-Line BRAF-Mutation-Positive Unresectable or Metastatic Malignant Melanoma in the United States: 2020-2030
          • Patient-Share Dynamics of Key Therapies in Third- and Fourth-Line BRAF-Mutation-Positive Unresectable or Metastatic Malignant Melanoma in Europe: 2020-2030
          • Patient-Share Dynamics of Key Therapies in Second-Line BRAF Wild-Type Unresectable or Metastatic Malignant Melanoma in the United States: 2020-2030
          • Patient-Share Dynamics of Key Therapies in Second-Line BRAF Wild-Type Unresectable or Metastatic Malignant Melanoma in Europe: 2020-2030
          • Patient-Share Dynamics of Key Therapies in Third- and Fourth-Line BRAF Wild-Type Unresectable or Metastatic Malignant Melanoma in the United States: 2020-2030
          • Patient-Share Dynamics of Key Therapies in Third- and Fourth-Line BRAF Wild-Type Unresectable or Metastatic Malignant Melanoma in Europe: 2020-2030
      • Forecast
        • Market Forecast Assumptions
        • Market Forecast Dashboard
      • Etiology and Pathophysiology
        • Disease Overview
          • Disease Pathophysiology
            • Progression of Malignant Melanoma
            • Progression of Malignant Melanoma
          • Staging and Classification
            • Classification and Staging of Malignant Melanoma
            • AJCC TNM Classification System for Cutaneous Malignant Melanoma: Eighth Edition
            • AJCC Staging System for Cutaneous Malignant Melanoma: Eighth Edition
            • Current WHO Histological Classification of Malignant Melanoma Subtypes
            • Histopathological and Clinical Prognostic Factors for Malignant Melanoma
            • Survival Rates for Malignant Melanoma
          • Key Pathways and Drug Targets
            • Immune Checkpoint Inhibitors
            • Drug Targets for Malignant Melanoma
            • Key Targets and Signaling Pathways for Malignant Melanoma
        • Epidemiology
          • Key Findings
            • Epidemiology Populations
              • Disease Definition
              • Methods
              • Sources Used for Diagnosed Incidence of Malignant Melanoma
              • Diagnosed Incident Cases of Malignant Melanoma: 2020-2030
              • Disease Definition
              • Methods
              • Sources Used for Stage Distribution of Malignant Melanoma
              • Diagnosed Incident Cases of Malignant Melanoma by Stage Distribution: 2020-2030
              • Disease Definition
              • Methods
              • Sources Used for Malignant Melanoma Recurrent Incidence
              • Recurrent Incident Cases of Malignant Melanoma in the Major Pharmaceutical Markets: 2020-2030
              • Malignant Melanoma Patient Flow
              • Drug-Treatable Cases of Malignant Melanoma: 2020-2030
              • Drug-Treated Cases of Malignant Melanoma: 2020-2030
          • Current Treatment
            • Key Findings
              • Treatment Goals
                • Key Endpoints Used in Clinical Trials for Malignant Melanoma
              • Key Current Therapies
                • Overview
                • Mechanism of Action of Key Current Drug Classes Used for Malignant Melanoma
                • Current Treatments Used for Malignant Melanoma
                • Market Events Impacting the Use of Key Current Therapies in Malignant Melanoma
                • Key Results From Select Trials Investigating Yervoy for the Treatment of Malignant Melanoma
                • Ongoing Clinical Development of Yervoy
                • Key Ongoing Clinical Trials of Yervoy in the Treatment of Malignant Melanoma
                • Expert Insight: Yervoy
                • Key Results From Select Clinical Trials Investigating Keytruda for the Treatment of Malignant Melanoma
                • Ongoing Clinical Development of Keytruda
                • Key Ongoing Clinical Trials of Keytruda in the Treatment of Malignant Melanoma
                • Expert Insight: Keytruda
                • Key Results From Select Clinical Trials Investigating Opdivo for the Treatment of Malignant Melanoma
                • Ongoing Clinical Development of Opdivo
                • Key Ongoing Clinical Trials of Opdivo in the Treatment of Malignant Melanoma
                • Expert Insight: Opdivo
                • Key Results From Select Clinical Trials Investigating Opdivo Plus Yervoy Combination Therapy for the Treatment of Malignant Melanoma
                • Ongoing Clinical Development of Opdivo and Yervoy Combination Therapy
                • Key Ongoing Clinical Trials of Opdivo and Yervoy Combination Therapy in the Treatment of Malignant Melanoma
                • Expert Insight: Opdivo and Yervoy Combination Therapy
                • Key Results From Select Clinical Trials Investigating Tecentriq for the Treatment of Malignant Melanoma
                • Ongoing Clinical Development of Tecentriq
                • Key Ongoing Clinical Trials of Tecentriq in the Treatment of Malignant Melanoma
                • Expert Insight: Tecentriq for the Treatment of Malignant Melanoma
                • Advantages and Disadvantages of Zelboraf
                • Ongoing Clinical Development of Zelboraf
                • Expert Insights: Zelboraf
                • Advantages and Disadvantages of Tafinlar
                • Ongoing Clinical Development of Tafinlar
                • Expert Insight: Tafinlar
                • Advantages and Disadvantages of Mekinist
                • Ongoing Clinical Development of Mekinist
                • Key Results From Select Clinical Trials Investigating Tafinlar and Mekinist Combination Therapy for the Treatment of Malignant Melanoma
                • Ongoing Clinical Development of Tafinlar and Mekinist Combination Therapy
                • Key Ongoing Clinical Trials of Tafinlar and Mekinist Combination Therapy in the Treatment of Malignant Melanoma
                • Expert Insight: Tafinlar and Mekinist Combination Therapy
                • Key Results From Select Clinical Trials Investigating Zelboraf and Cotellic Combination Therapy for the Treatment of Malignant Melanoma
                • Ongoing Clinical Development of Zelboraf and Cotellic Combination Therapy
                • Expert Insight: Zelboraf and Cotellic Combination Therapy
                • Key Results From Select Clinical Trials Investigating Braftovi and Mektovi Combination Therapy for the Treatment of Malignant Melanoma
                • Ongoing Clinical Development of Braftovi and Mektovi Combination Therapy
                • Key Ongoing Clinical Trials of Braftovi Plus Mektovi in the Treatment of Malignant Melanoma
                • Expert Insight: Braftovi and Mektovi Combination Therapy
                • Key Results From Select Clinical Trials Investigating Imlygic for the Treatment of Malignant Melanoma
                • Ongoing Clinical Development of Imlygic
                • Key Ongoing Clinical Trials of Imlygic in the Treatment of Malignant Melanoma
                • Expert Insight: Imlygic
                • Advantages and Disadvantages of Cytokines
                • Advantages and Disadvantages of Cytotoxic Agents
              • Medical Practice
                • Resectable Malignant Melanoma: Stage llB-lll
                • First-Line Unresectable or Metastatic BRAF-Mutation-Positive Malignant Melanoma
                • First-Line Unresectable or Metastatic BRAF Wild-Type Malignant Melanoma
                • Second-Line Unresectable or Metastatic BRAF-Mutation-Positive Malignant Melanoma
                • Second-Line Unresectable or Metastatic BRAF Wild-Type Malignant Melanoma
                • Third- and Fourth-Line Unresectable or Metastatic Malignant Melanoma
                • Patient Characteristics Influencing Drug Selection in Malignant Melanoma
                • Region-Specific Treatment Practices
                • Treatment Decision Tree for Malignant Melanoma: United States
                • Treatment Decision Tree for Malignant Melanoma: Europe
                • Treatment Decision Tree for Malignant Melanoma: Japan
            • Unmet Need Overview
              • Current and Future Attainment of Unmet Needs in Malignant Melanoma
              • Top Unmet Needs in Malignant Melanoma: Current and Future Attainment
              • Expert Insights: Unmet Need in Malignant Melanoma
            • Emerging Therapies
              • Key Findings
                • Key Emerging Therapies
                  • Key Therapies in Development for Malignant Melanoma
                  • Estimated Market Authorization Dates of Key Emerging Therapies for the Treatment of Malignant Melanoma
                  • Key Results From Select Clinical Trials Investigating Spartalizumab for the Treatment of Malignant Melanoma
                  • Analysis of Clinical Development Program for Spartalizumab
                  • Key Ongoing Clinical Trials of Spartalizumab in the Treatment of Malignant Melanoma
                  • Expert Insight: Spartalizumab
                  • Expectations for Market Authorization and Sales Opportunity of Spartalizumab in Malignant Melanoma
                  • Key Results From Select Clinical Trials Investigating Relatlimab for the Treatment of Malignant Melanoma
                  • Analysis of the Clinical Development Program for Relatlimab
                  • Key Ongoing Clinical Trials of Relatlimab in the Treatment of Malignant Melanoma
                  • Expert Insight: Relatlimab
                  • Expectations for Market Authorization and Sales Opportunity of Relatlimab in Malignant Melanoma
                  • Key Results From Select Clinical Trials Investigating Seviprotimut-L for the Treatment of Malignant Melanoma
                  • Analysis of Clinical Development Program for Seviprotimut-L
                  • Key Ongoing Clinical Trials of Seviprotimut-L in the Treatment of Malignant Melanoma
                  • Expert Insight: Seviprotimut-L
                  • Expectations for Market Authorization and Sales Opportunity of Seviprotimut-L in Malignant Melanoma
                  • Key Results From Select Clinical Trials Investigating PV-10 for the Treatment of Malignant Melanoma
                  • Analysis of Clinical Development for PV-10
                  • Key Ongoing Clinical Trials of PV-10 in the Treatment of Malignant Melanoma
                  • Expert Insight: PV-10
                  • Expectations for Market Authorization and Sales Opportunity of PV-10 in Malignant Melanoma
                  • Key Results From Select Clinical Trials Investigating Nidlegy for the Treatment of Malignant Melanoma
                  • Analysis of the Clinical Development Program for Nidlegy
                  • Key Ongoing Clinical Trials of Nidlegy in the Treatment of Malignant Melanoma
                  • Expert Insight: Nidlegy
                  • Expectations for Launch and Sales Opportunities of Nidlegy in Malignant Melanoma
                  • Key Results From Select Clinical Trials Investigating Modtylso for the Treatment of Malignant Melanoma
                  • Analysis of the Clinical Development Program for Modtylso
                  • Key Ongoing Clinical Trials of Modtylso in the Treatment of Malignant Melanoma
                  • Expert Insights: Modtylso
                  • Expectations for Market Authorization and Sales Opportunity of Modtylso in Malignant Melanoma
                  • Key Results From Select Clinical Trials Investigating Vidutolimod for the Treatment of Malignant Melanoma
                  • Analysis of the Clinical Development Program for Vidutolimod
                  • Key Ongoing Clinical Trials of Vidutolimod in the Treatment of Malignant Melanoma
                  • Expert Insights: Vidutolimod
                  • Expectations for Launch and Sales Opportunities of Vidutolimod in Malignant Melanoma
                  • Key Results From Select Clinical Trials Investigating Lenvima for the Treatment of Malignant Melanoma
                  • Analysis of the Clinical Development Program for Lenvima
                  • Key Ongoing Clinical Trials of Lenvima in the Treatment of Malignant Melanoma
                  • Expert Insights: Lenvima
                  • Expectations for Launch and Sales Opportunities of Lenvima in Malignant Melanoma
                  • Key Results From Select Clinical Trials Investigating Bempegaldesleukin for the Treatment of Malignant Melanoma
                  • Analysis of the Clinical Development Program for Bempegaldesleukin
                  • Key Ongoing Clinical Trials of Bempegaldesleukin in the Treatment of Malignant Melanoma
                  • Expert Insight: Bempegaldesleukin
                  • Expectations for Market Authorization and Sales Opportunities of Bempegaldesleukin in Malignant Melanoma
                  • Key Results From Select Clinical Trials Investigating Lifileucel for the Treatment of Malignant Melanoma
                  • Analysis of the Clinical Development Program for Lifileucel
                  • Key Ongoing Clinical Trials of Lifileucel in the Treatment of Malignant Melanoma
                  • Expert Insight: Lifileucel
                  • Expectations for Market Authorization and Sales Opportunities of Lifileucel in Malignant Melanoma
                • Early-Phase Pipeline Analysis
                  • Select Compounds in Phase II Development for Malignant Melanoma
              • Access and Reimbursement Overview
                • Region-Specific Reimbursement Practices
                  • Key Market Access Considerations in Malignant Melanoma: United States
                  • General Reimbursement Environment: United States
                  • Key Market Access Considerations in Malignant Melanoma: EU5
                  • General Reimbursement Environment: EU5
                  • Key Market Access Considerations in Malignant Melanoma: Japan
                  • General Reimbursement Environment: Japan
              • Appendix
                • Malignant Melanoma Bibliography

            launch Related Market Assessment Reports